ESR1 and cancer: In cancer, when RA binds to RARα, alternative transcriptional partners, as estrogen receptor α (ERα), are recruited into the nucleus, thus promoting cell proliferation, drug resistance, and inhibition of apoptosis through the activation of c-MYC, cyclin D1 and ALDH1A1 itself (Figure 1A) (15, 16).